Nasdaq · Healthcare

Whitehawk Therapeutics, Inc. (WHWK)

As-reported financials and recent SEC filings for Whitehawk Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$7.1M

Net income

$-20.6M

Net margin

—

Diluted EPS

$-0.33

ROE

-15.1%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$7.1M	$26.0M	$24.4M	$15.2M	$14.0M
Gross profit	$6.4M	$23.0M	$21.5M	$13.9M	—
Operating income	$-114.4M	$-67.5M	$-71.9M	$-62.7M	$-111.2M
Net income	$-20.6M	$-63.7M	$-65.8M	$-60.5M	$-110.1M
Diluted EPS	$-0.33	$-1.18	$-1.22	$-1.34	$-2.07

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-15

42026-06-15

42026-06-15

42026-06-15

42026-06-15

42026-06-15

42026-06-15

8-K2026-06-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on WHWK

Search Whitehawk Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.